This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Henry Schein (HSIC) Tops Q4 Earnings, Reaffirms '17 View
by Zacks Equity Research
Henry Schein, Inc. (HSIC) reported adjusted earnings per share of $1.88 in the fourth quarter of 2016, up 12.6% year over year and surpassed the Zacks Consensus Estimate by 2.2%.
Ecolab's (ECL) Earnings, Revenues Miss Estimates in Q4
by Zacks Equity Research
Ecolab Inc. (ECL) reported fourth-quarter 2016 adjusted earnings of $1.25 per share, which missed the Zacks Consensus Estimate of $1.27.
Medtronic (MDT) Beats on Q3 Earnings, Retains Sales View
by Zacks Equity Research
Medtronic plc'S (MDT) third-quarter fiscal 2017 Adjusted earnings per share (EPS) came in at $1.12, a penny ahead of the Zacks Consensus Estimate.
Henry Schein to Acquire SAS to Strengthen Dental Offerings
by Zacks Equity Research
Henry Schein Inc. (HSIC) announced its decision to acquire Southern Anesthesia + Surgical (SAS).
GNC Holdings (GNC) Misses Q4 Earnings, Revenues Decline Y/Y
by Zacks Equity Research
GNC Holdings Inc. (GNC) reported fourth-quarter 2016 adjusted earnings per share (EPS) of 37 cents, down 88.1% and also missed the Zacks Consensus Estimate by 81.1%.
Medtronic's Freezor Xtra Catheter Gains FDA Nod for AVNRT
by Zacks Equity Research
Medtronic plc (MDT) recently announced the receipt of U.S. FDA approval for its Freezor Xtra Cryoablation Catheter to treat patients with atrioventricular nodal re-entrant tachycardia.
LabCorp (LH) Q4 Earnings and Revenues Beat, Offers View
by Zacks Equity Research
Laboratory Corporation of America Holdings (LH) or LabCorp reported fourth-quarter 2016 adjusted earnings per share (EPS) of $2.15, up 8.6% from the year-ago quarter.
Chemed (CHE) Misses Q4 Earnings, Sales; Offers '17 View
by Zacks Equity Research
Chemed Corp.'s (CHE) fourth-quarter 2016 adjusted earnings per share (EPS) was $2.02, missing the Zacks Consensus Estimate by 4.3%.
Omnicell (OMCL) Q4 Earnings Deteriorate Y/Y, Revenues Miss
by Zacks Equity Research
Omnicell, Inc. (OMCL) reported a breakeven in fourth-quarter 2016 earnings per share (EPS), a deterioration from the year-ago earnings of 5 cents.
Cynosure (CYNO) to be Acquired by Hologic in $1.65B Deal
by Zacks Equity Research
Cynosure, Inc. (CYNO), announced that it has entered into a definitive merger agreement with Hologic, Inc. (HOLX).
Genomic Health (GHDX) Earnings Surpass Estimates in Q4
by Zacks Equity Research
Genomic Health, Inc. (GHDX) reported fourth-quarter 2016 earnings per share of 4 cents, reflecting an improvement from the year-ago quarter's loss figure of 8 cents.
Medtronic (MDT) Adds New Tools, Expands Coronary Suite
by Zacks Equity Research
Medtronic plc (MDT) recently added DxTerity Diagnostic Angiography Catheter line and several transradial-specific products to its market-leading coronary portfolio.
Bruker (BRKR) Beats on Q4 Earnings, Issues 2017 Guidance
by Zacks Equity Research
Bruker Corporation (BRKR) reported fourth quarter 2016 adjusted EPS of 46 cents, up 21.1% year over year and also surpassed the Zacks Consensus Estimate of 37 cents.
Omnicell Partners with DCH Health for Sterile Compounding
by Zacks Equity Research
Omnicell, Inc. (OMCL) recently formed an alliance with West Alabama's community-based health service provider, DCH Health System on sterile compounding operations.
Varian (VAR) Wins Competitive Bid for Six Shanghai Hospitals
by Zacks Equity Research
Varian Medical Systems, Inc. (VAR) recently announced that it has won a competitive bid in Shanghai.
STERIS (STE) Cuts 2017 View: Will it See Gloomy Days Ahead?
by Zacks Equity Research
On Feb 09, we issued an updated research report on Ohio-based STERIS plc (STE).
Mead Johnson-Reckitt Benckiser Mega Deal: A Strategic Fit?
by Zacks Equity Research
Pediatric nutrition manufacturer Mead Johnson Nutrition Company (MJN) recently announced an agreement to be acquired by British consumer-products maker, Reckitt Benckiser Group plc.
NuVasive (NUVA) Beats Q4 Earnings, Revenues; Guides 2017
by Zacks Equity Research
NuVasive, Inc. (NUVA) reported fourth-quarter 2016 adjusted earnings per share (EPS) of 53 cents, reflecting a 51.4% surge from the year-ago quarter.
Myriad Genetics (MYGN): Q2 Impressive, 2017 View a Drag
by Zacks Equity Research
On Feb 8, we issued an updated research report on Salt Lake City, UT-based molecular diagnostic company Myriad Genetics Inc. (MYGN).
Zimmer Biomet (ZBH) Launches Subchondroplasty Procedure
by Zacks Equity Research
Zimmer Biomet Holdings, Inc. (ZBH), a leading player in the musculoskeletal healthcare space, recently announced the global launch of its Subchondroplasty (SCP) Procedure.
CVS Health (CVS) Beats on Q4 Earnings, Retains '17 View
by Zacks Equity Research
CVS Health Corporation (CVS) reported fourth-quarter 2016 adjusted earnings per share (EPS) of $1.71, up 11.8% year over year.
Quest Diagnostics Partners with Veracyte for Cancer Testing
by Zacks Equity Research
Quest Diagnostics Incorporated (DGX) has recently entered into an agreement with genomic diagnostics company Veracyte, Inc. (VCYT), for the extended access of Afirma Gene Expression Classifier (GEC).
Myriad Genetics (MYGN) Beats on Q2 Earnings, Narrows View
by Zacks Equity Research
Myriad Genetics Inc. (MYGN) reported adjusted earnings per share (EPS) of 26 cents in the second quarter of fiscal 2017, down 42.2% year over year.
Steris (STE) Q3 Dismal: Earnings Miss Estimates, View Cut
by Zacks Equity Research
Steris Plc (STE) reported third-quarter fiscal 2017 adjusted earnings per share (EPS) of 98 cents, in line with the year-ago quarter.
Haemonetics (HAE) Beats Q3 Earnings & Revenue Estimates
by Zacks Equity Research
Haemonetics Corporation (HAE) reported adjusted earnings per share (EPS) of 43 cents in the third quarter of fiscal 2017, beating the Zacks Consensus Estimate by 7.5%.